News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Proteo Biotech AG (PTEO.OB) And Proteo Inc. (PTEO.OB) Anti-Inflammatory Agent "Elafin" Has Been Successfully Tested In A Phase I Clinical Trial


12/13/2005 11:50:24 AM

KIEL, Germany--(BUSINESS WIRE)--Dec. 13, 2005--The first phase in the clinical trial of the newly developed drug Elafin has been successfully completed as announced by Proteo Biotech AG, a wholly owned subsidiary of Proteo Inc. (OTCBB:PTEO). Elafin, a recombinant human protein, is intended for the treatment of inflammatory diseases and is administered intravenously. The trial aimed to assess the safety and tolerability of this biotechnologically manufactured drug.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES